Guidance
Skip Standards and indicators submenu
Quality standards
Our quality standards set out priority areas for quality improvement. They highlight areas with identified variation in current practice.
View our quality standards
How to use our quality standards
The timeline for developing quality standards
Help us develop quality standards
Selecting and prioritising quality standards topics
About quality standards
Indicators
Our indicators measure outcomes that reflect the quality of care, or processes linked by evidence to improved outcomes.
View list of indicators
Learn about the committee that develops indicators
About indicators
Skip Life sciences submenu
Life Sciences
We offer tailored support to industry during product development. Our expertise can help you build the evidence needed to achieve market access.
View life sciences
Get support from NICE
NICE Advice service
Trusted, unrivalled expertise.
Make an enquiry
Contact us to discuss your requirements.
Innovative Licensing and Access Pathway (ILAP)
Streamlining patient access to safe, financially sustainable and innovative medicines.
Learn how we evaluate technologies
Health technology evaluation and topic selection manuals
Updated manuals for methods, processes and topic selection.
Digital health technologies
Accelerating our efforts to deliver innovation to the health and care system.
Evidence standards framework
Using the best available evidence to develop recommendations that guide decisions in health, public health and social care.
Our guidance programmes
Ensuring new technologies are clinically effective and offer economic value.
Register your product
Non-pharmaceutical
NHS Innovation Service is a clear and simple point of entry for health technologies to access support and national evaluation programmes.
Pharmaceutical
UK PharmaScan is a database of new medicines, indications and formulations in the pharmaceutical pipeline.
Find published and proposed evaluations
Diagnostics
Guidance on measurements and tests used to evaluate a patient's condition.
Medical technologies
Guidance on medical technologies put forward to NICE by manufacturers.
Technology appraisals
Guidance on new and existing medicines and treatments in the NHS.
Highly specialised technologies
Guidance on the use of highly specialised medicines and treatments.
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
Skip About submenu
About
NICE helps practitioners and commissioners get the best care to patients, fast, while ensuring value for the taxpayer.
Explore about
Our programmes
Learn about the information we produce.
Guidance
Advice
Quality standards
Indicators
Digital health
Topic selection
Get involved
Understand how decisions are made:
Attend a committee meeting
Comment on draft guidance:
Guidance in consultation
Be part of a guidance committee:
Join a committee
Help develop our products:
Register as a stakeholder
Putting you at the heart of our work:
Public involvement
What we do
Social care
Life sciences
NICE international
Patient safety
Shared decision making
View all What we do
Into practice
Social care quick guides
Measuring the use of NICE guidance
Resource planner
View all Into practice
Who we are
The board
The NICE strategy 2021 to 2026
Corporate publications
View all Who we are
- Contact us
- Jobs

Menopause: identification and management

NICE guideline
Reference number: NG23
Published: 12 November 2015
Last updated: 07 November 2024

Menopause: equality impact assessment

Menopause: equality impact assessment

Menopause: equality impact assessment
27 July 2015
(161.68 Kb 47 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 27 July 2015

Consultation questions (PDF 302 KB)

Published:

13 August 2019
Evidence tables (PDF 1.65 MB)

Published:

13 August 2019
Surveillance review proposal (PDF version) (PDF 176 KB)

Published:

13 August 2019
Consultation summary of evidence (PDF version) (PDF 329 KB)

Published:

13 August 2019
Consultation summary of evidence (Online version)
Surveillance review proposal (online version)
Stakeholder list (PDF 112 KB)

Published:

12 August 2019
Equality impact assessment (PDF 243 KB)

Published:

01 December 2015
Committee member list (PDF 384 KB)

Published:

12 November 2015
Consultation comments and responses (PDF 3.1 MB)

Published:

12 November 2015
Equality impact assessment (PDF 243 KB)

Published:

12 November 2015
Equality impact assessment (consultation) (PDF 67 KB)

Published:

23 July 2015
Full guideline (PDF 3.43 MB)

Published:

01 June 2015
Draft guideline (NICE) (PDF 497 KB)

Published:

01 June 2015
Equality impact assessment (PDF 162 KB)

Published:

27 July 2015
Appendices A-G (PDF 6.34 MB)

Published:

01 June 2015
Appendix H (PDF 8.65 MB)

Published:

01 June 2015
Appendices I-K (PDF 6.82 MB)

Published:

01 June 2015
Appendix L (PDF 2.61 MB)

Published:

01 June 2015
Review questions (PDF 33 KB)

Published:

24 March 2015
Search strategies (PDF 1.09 MB)

Published:

24 March 2015
Economic plan (PDF 120 KB)

Published:

24 March 2015
Stakeholder consultation comments table (PDF 425 KB)

Published:

12 August 2013
Final scope (PDF 210 KB)

Published:

13 December 2013
Scoping workshop notes (PDF 144 KB)

Published:

24 May 2013
Draft scope (PDF 191 KB)

Published:

24 May 2013
List of registered stakeholders (PDF 96 KB)

Published:

01 June 2015
GDG membership list (PDF 85 KB)

Published:

24 April 2015
GDG 5 Minutes (PDF 130 KB)

Published:

28 May 2014
GDG 4 Minutes (PDF 129 KB)

Published:

28 May 2014
GDG 2 and 3 minutes (PDF 128 KB)

Published:

03 January 2014
GDG 1 minutes (PDF 123 KB)

Published:

03 January 2014
Stakeholder consultation comments table (PDF 425 KB)

Published:

12 August 2013
Final scope (PDF 210 KB)

Published:

13 December 2013
Scoping workshop notes (PDF 144 KB)

Published:

24 May 2013
Draft scope (PDF 191 KB)

Published:

24 May 2013
List of registered stakeholders (PDF 96 KB)

Published:

01 June 2015